Imatinib Crescent Pharma

Imatinib, the active ingredient in Imatinib Crescent Pharma, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Crescent Pharma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib is a tyrosine kinase inhibitor used primarily in hematologic and solid‑tumor indications.

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and induces remission. - Gastrointestinal stromal tumor (GIST): blocks tumor growth pathways and improves progression‑free survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to disease control and prolongs survival.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, especially around the ankles. - Muscle cramps: intermittent skeletal muscle discomfort. - Fatigue: generalized tiredness. - Diarrhea: loose stools, often self‑limiting. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Neutropenia: significant drop in white blood cells, increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiotoxicity: reduced left‑ventricular ejection fraction. - Severe fluid retention: pleural effusion or pericardial effusion. - Anaphylaxis: rare severe allergic reaction. - Hemorrhage: bleeding events, especially when combined with anticoagulants.

Careful monitoring and patient education are essential when using Imatinib.

- Monitor blood counts: perform regular CBC to detect neutropenia or anemia. - Assess liver function: check transaminases before and during therapy. - Evaluate cardiac function: baseline ECG and periodic echocardiography for patients at risk. - Avoid use in severe hepatic impairment: contraindicated due to reduced metabolism. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib may interact with several concomitant medicines, requiring dose adjustments or monitoring.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations, raising toxicity risk. - CYP3A4 inducers (e.g., rifampin): lower drug levels, reducing efficacy. - Warfarin: potentiates anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce oral absorption of Imatinib. - Live vaccines: potential for reduced immunogenicity. - Loop diuretics: can exacerbate fluid retention and edema.